Media Releases

For all media enquiries, please contact

Genomiqa partners with Icon Group to validate an Australian-first diagnostic

Brisbane Cancer patients will soon have access to the latest in personalised cancer diagnoses with the launch of a validation study of genomiQa’s whole genome analysis platform, CapeDX, in partnership with Icon Group.

genomiQa is a spin-off company from QIMR Berghofer Medical Research Institute and is focused on bringing precision whole genome analytics into routine clinical practice.

genomiQa’s CapeDX platform supports the personalisation of a patient’s cancer treatment by analysing the whole genome of the patient (hereditary) and their cancer tumour.

The pilot study will be conducted in collaboration with Icon Cancer Centre Wesley – part of the global Icon Group – and will involve genomic testing of up to 15 patients.

Based on genomiQa’s analysis of the patients’ genomes, each patient may be matched to the most suitable treatment option for their cancer, including approved drugs and those available through clinical trials.

genomiQa’s CEO, Colin Albert, said the validation study was a major step towards rolling out the company’s precision analytics platform more widely.

“Through this pilot study, we will validate genomiQa’s offerings and service delivery,” Mr Albert said.

“Our partnership with Icon Group is essential to the success of the project, and the fact that Icon has a rich history of supporting world leading research is a key benefit.”

Icon Group’s Director of Research, Dr John Bashford, said the company’s principle was that every patient deserved the opportunity to have the best and latest treatment that was appropriate for them.

“We are delighted to offer patients the opportunity to access this Australian-first study and ensure treatment is personalised to their unique genomic information,” Dr Bashford said.

“No other technique currently simultaneously examines the hereditary drivers of cancers as well as more than 1500 known cancer genes in a tumour.”

The CEO of Rare Cancer Australia, Richard Vines, has welcomed the pilot study.

“The challenge we face is that more than 145 000 people are diagnosed with cancer in Australia every year, and we have been treating the symptoms not the root cause,” Mr Vines said.

“But with the advent now of technology like genomiQa’s, it may give patients more reason to hope.”

This project is supported by the Commonwealth Department of Industry, Science, Energy and Resources through the Entrepreneurs’ Programme, which has contributed nearly $500 000 of matched funding.

The rest of the funding was provided by QIMR Berghofer Medical Research Institute, which supports the commercialisation of discoveries by the Institute’s scientists.

This Commonwealth Government grant will also support the accreditation of genomiQa’s whole genome analysis product for rare diseases, Gulf DX.


Media contacts:

genomiQa Pty Ltd / QIMR Berghofer Medical Research Institute / ICON / 0458 650 200.
Rare Cancers Australia:


Further information:

genomiQa Pty Ltd is a whole genome analysis company focusing on platform technologies to discover new medicines and to provide a personalised diagnosis for patients living with cancer and rare diseases. genomiQa is a spin-out company from QIMR Berghofer Medical Research Institute and has benefited from their internal commercialisation accelerators.

QIMR Berghofer Medical Research Institute is one of Australia’s most successful medical research institutes. It focuses on the research areas of cancer, infectious diseases, mental health and chronic disorders. The Institute’s priority is to translate research from the laboratory bench to the hospital bedside and the broader community to improve human health. It does that by developing new and better prevention strategies, diagnostic tools and treatments.

Icon Group has a strong history in cancer research, operating the largest private cancer clinical trials program in Australia. The depth and experience within Icon’s dedicated research arm enables patients and clinicians to access key clinical trials across their global Icon Cancer Centre network. They deliver national and international clinical trials across haematology, medical oncology and radiation oncology, with their phase 1 program playing an important role in the provision of new and novel therapies to people with rare and less-common cancers.

Icon Cancer Centre Wesley is part of the global Icon Group and has proudly delivered exceptional cancer care within The Wesley Medical Centre for more than 30 years. The centre offers the latest in cancer treatment, including chemotherapy, specialised therapies for all solid and haematological malignancies and access to clinical trials.

Rare Cancers Australia (RCA) is determined to increase awareness, highlight the need for further research and initiate policy discussion and action to improve the lives and outcomes of all Australians living with a rare or less common cancer. RCA is currently working with governments, clinicians and industry for change.